USANA Health Sciences: amends credit agreement for $75,000,000 revolving facility

What happened

• USANA Health Sciences, Inc. entered into a First Amendment to its Third Amended and Restated Credit Agreement on Sep 30, 2026.
• The Credit Agreement provides for a revolving credit facility of $75,000,000 that matures on Jun 27, 2030 (which may, upon request of the Company, be increased by an amount notice exceeding $200,000,000).

Key details

• Beginning with the fiscal quarter ending Oct 3, 2026, the Company must maintain Consolidated EBITDA of at least $100,000,000 for each trailing four-fiscal-quarter period; if the lenders’ aggregate Revolving Exposure is $50,000,000 or less on the last day of the period, the minimum is $70,000,000 for that period.
• The annual general asset sale basket limit in Section 7.05(g) increases from $500,000 to $2,500,000.
• New Section 7.05(h) permits USANA Australia Pty, Ltd to sell real property in Sydney, Australia and apply the net proceeds as it determines appropriate in its reasonable business judgment.
• Sale and leaseback transactions remain prohibited except as agreed by the Required Lenders or for a disposition permitted under new Section 7.05(h); the Amendment also amends and restates the definition of “Sale and Leaseback Transaction.”
• The loan parties reaffirmed their obligations and liens under the Loan Documents, confirmed certain representations and warranties, and stated that no default or event of default exists under the Loan Documents.

Why it may matter

• Item 1.01 (entry into a material definitive agreement) reports the First Amendment to the Credit Agreement and the covenant and transaction changes listed above.
• Item 2.03 (creation of a direct financial obligation) reports the Company’s continued obligations and secured borrowing capacity under the amended revolving credit facility.
  This filing does not show why the company acted.